Dynamic Advisor Solutions LLC Cuts Stock Position in Boston Scientific Co. (NYSE:BSX)

Dynamic Advisor Solutions LLC lessened its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 92.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,775 shares of the medical equipment provider's stock after selling 58,598 shares during the period. Dynamic Advisor Solutions LLC's holdings in Boston Scientific were worth $427,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new stake in Boston Scientific during the third quarter valued at $28,000. Dunhill Financial LLC lifted its stake in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific during the third quarter valued at approximately $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BSX. Bank of America increased their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Citigroup boosted their price target on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Finally, Mizuho boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Three equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $97.26.

Insider Activity

In related news, EVP John Bradley Sorenson sold 4,119 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares of the company's stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.1 %

BSX stock traded down $0.15 during trading on Tuesday, hitting $102.12. The company had a trading volume of 3,846,442 shares, compared to its average volume of 5,677,728. The firm has a market capitalization of $150.51 billion, a P/E ratio of 84.43, a PEG ratio of 2.63 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52-week low of $60.78 and a 52-week high of $102.93. The company has a 50 day simple moving average of $92.50 and a 200-day simple moving average of $85.63.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.